Navigation Links
Free Activin A ELISA Test

ProductsFree Activin A ELISA Test
Company Diagnostic Systems Laboratories, Inc.
Item Free Activin A ELISA Test
Features Inquire
Description Activins are polypeptide hormones which belong to the transforming growth factor- (TGF-) superfamily. The TGF- superfamily is a large group of extra-cellular growth factors which control many aspects of development, reproductive function and tumor formation (1). Other members incude TGF-s, bone morphogenetic proteins, growth differentiation factors, AMH/MIS (Anti-Mullerian Hormone/Mullerian Inhibiting Substance) and Inhibins.

Activins and Inhibins are structurally related gonadal dimeric glycoproteins defined by their ability to modulate the synthesis and release of follicle-stimulating hormone (FSH) from the anterior pituitary gland. Activins are homo- or heterodimers consisting of A or B subunits producing Activin A, B, and AB, and have been shown to stimulate FSH release. Inhibins are heterodimers consisting of a common a-subunit linked to either a A subunit (Inhibin A) or B subunit (Inhibin B) by disulfide bridges, and in contrast to the Activins, inhibit FSH release. Messenger RNA studies demonstrate that both Inhibin and Activin are most abundant in the ovary and testis, but can be found in a variety of other tissues (2). In addition to their endocrine role, these proteins have been shown to affect the growth and differentiation of a number of cell types, including cultured rat anterior pituitary cells, gonadal and neuronal cell lines, and hematopoietic progenitor and erythroleukemia cells (2).

Two binding proteins have been described for the Activins and Inhibins: Follistatin and a-2 macroglobulin. Activins are bound with high affinity to follistatin with a possible regulatory role, while both inhibins and activins are found to bind reversibly with a2-macroglobulin (3).

Despite numerous studies investigating the circulating levels of the various activin molecules in numerous disease states, no clear physiological roles have been established other than the stimulatory action on pituitary FSH secretion. However, a number of recent studies have indicated that the measurement of Activin may be useful as a predictor of pre-eclampsia (4,5), preterm labor (6) and various oncological conditions (7).

  1. Chang H et al. Endocrine Rev 23: 787-823, 2002.
  2. Meunier H et al. Proc Natl Acad Sci USA 85: 247-251, 1988.
  3. Krummen LA et al. Endocrinology 132: 431-443, 1993.
  4. Muttukrishna S et al. Lancet 349:1285-1288, 1997.
  5. Muttukrishna S et al. Hum Reprod 15(7):1640-1645, 2000.
  6. Lockwood GM et al. Biol Reprod 57(6):1490-1494, 1997.
  7. Lambert-Messerlian GM et al. Gynecol Oncol 74(1):93-97, 1999.
Info Diagnostic Systems Laboratories, Inc.
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com

Related medicine products :

1. Free Activin B ELISA Test
2. Free Activin AB ELISA Test
3. Microplate ELISA Washers - Manual Microplate Washer
4. Microplate ELISA Washers - Automated Microplate Washer
5. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
6. RELISA ANA Screening System
7. BioCheck hCG ELISA
8. Human Chorionic Gonadotropin (HCG) ELISA Kit
9. Human PSA ELISA Kit
10. Total PSA ELISA Test
11. Free PSA ELISA
Microforceps: Claes ILM Forceps...
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps with "nail-like" end-gripping platforms; for precise grasping and improved visualization of thin membranes in the macular region....
Microforceps : Eckardt Endgripping Forceps...
Medicine Products:
(Date:7/6/2015)... ... July 06, 2015 , ... Dr. Lawrence Green is ... area patients. Kybella is a non-surgical method to dissolve fat cells and ... moderate to severe fat deposits under the chin, commonly known as a double chin. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Promero, a leading cloud ... Software Unified IP contact center solution hosted by Promero. Randstad Technologies,a leading ... its future call center platform. , Promero will implement and manage the ...
(Date:7/6/2015)... Newport News, VA (PRWEB) , ... July 06, ... ... announced today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® ... Bon Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an ...
(Date:7/6/2015)... ... 06, 2015 , ... Diabetes affects many of us and the Glycemic Load ... diabetes, the majority of which are Type 2. However, eight million do not know ... three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood sugar levels ...
(Date:7/6/2015)... Akron, OH (PRWEB) , ... July 06, 2015 , ... ... Home Health and Hospice received the Music & Memory Certification for hospice patients ... bringing the power of music not only to patients but also to their families ...
Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4
... With sights set on advanced science degrees and careers ... now have the highest honor they can garner for ... Eastham, a junior chemistry major, and Thomas Markovich, a ... Barry M. Goldwater Scholars for the 2011-2012 academic year. ...
... 6, 2011 Researchers at The Scripps Research Institute have found ... to pour in and activate an immune response. This process can ... it fallssuch as when immune cells are "called" from the body,s ... The study, recently published online ahead of print by Nature ...
... international panel of experts from The Heart Rhythm Society ... recommendations for all health care professionals about cardiovascular genetic ... Sessions. Silvia G. Priori, MD, PhD, a ... director of the Cardiovascular Genetics Program at NYU Langone ...
... National Academies Keck Futures Initiative announced today the recipients ... to support interdisciplinary research on imaging science. The ... such research, which was the subject of the eighth ... "We received far more high-quality proposals than funds available," ...
... A study published in the June 2011 issue of ... the association between patientphysician gender concordance and weight-related counseling ... and Johns Hopkins University found that obese male patients ... counseling than obese women seeing a female physician. ...
... Reporter , THURSDAY, May 5 (HealthDay News) -- You stand ... while you,re in an exercise facility than if you,re in ... Overall, 50 percent of cardiac arrest victims survived ... sort of exercise was happening, whereas only 36 percent of ...
Cached Medicine News:Health News:2 students named Goldwater Scholars, 2 receive honorable mention 2Health News:2 students named Goldwater Scholars, 2 receive honorable mention 3Health News:Scripps Research scientists show how shifts in temperature prime immune response 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 3Health News:New guidelines for cardiovascular genetic testing 2Health News:Keck Futures Initiative awards $1 million for 13 research projects 2Health News:Keck Futures Initiative awards $1 million for 13 research projects 3Health News:Keck Futures Initiative awards $1 million for 13 research projects 4Health News:Keck Futures Initiative awards $1 million for 13 research projects 5Health News:Weight-loss counseling most prevalent between male physicians and obese men 2Health News:Cardiac Arrest Less Deadly in Exercise Facilities, Study Finds 2Health News:Cardiac Arrest Less Deadly in Exercise Facilities, Study Finds 3
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015   ... will report financial results for its 2015 second quarter ... after the close of the market. The ... Pacific Time on Thursday, July 23, 2015, to discuss ... Cepheid,s website at http://ir.cepheid.com at least 15 ...
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. , ... AGN ), a leading global pharmaceutical company, and Oculeve, ... treatments for dry eye disease, today announced that they ... acquire Oculeve in an all-cash transaction.  Under the terms ... $125 million upfront payment and commercialization milestone payments related ...
(Date:7/6/2015)... July 6, 2015 Akcea Therapeutics, a ... ISIS ), announced today that the U.S. Food ... to volanesorsen (ISIS-APOCIII Rx ) for the treatment ... is a rare genetic disease characterized by extremely ... a Phase 2 study published in the NEJM ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6